HALO News and Press, Halozyme Therapeutics Inc. From 11/02/20

Halozyme Therapeutics (HALO): Q3 GAAP EPS of $0.25 beats by $0.05.Revenue of $65.32M (+41.3% Y/Y) beats by $5.97M.Raises 2020 Guidance: Revenues: $250-260M up from $230-245M and EPS of $0.80-0.85, up from $0.60-$0.75.Press Release For further details see: Halozyme Therapeutics EPS ...

Halozyme Reports Third Quarter 2020 Results And Raises Full Year 2020 Guidance - Reports Third Quarter 2020 Revenue of $65.3 million and Earnings Per Share of $0.25 - - Successful Launch of DARZALEX® SC with ENHANZE® Drives 44% Year-over-year and 51% Sequential Gro...

The best sectors to focus your attention on now. The highest-rated stocks worth adding to your watch list. Why high-volatility ahead of elections could create a great buy opportunity. For further details see: If Stocks Tumble On Election Worries, Here Are The Top Stocks ...

Halozyme To Host THIRD Quarter 2020 Financial Results webcast and Conference Call PR Newswire SAN DIEGO, Oct. 22, 2020 SAN DIEGO , Oct. 22, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call ...

Genmab has continued to make great progress since my initial coverage a year ago. The company's portfolio of current and future therapeutics in association with world-class partners bodes well for continued breakthroughs in the fight against cancer. However, one issue of concern m...

Puma Biotechnology reports positive Neratinib Phase III data. Y-mAbs Therapeutics receives FDA rejection for omburtamab BLA. Halozyme Therapeutics fortifies collaboration with Argenx for Enhanze technology. For further details see: Puma's Positive Neratinib Data, And Oth...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. U.S. House hints at Big Tech breakupA House antitrust subcommittee report due this week on big tech - Amazon.com (AMZN), Apple (AAPL), Facebook (FB) and Al...

Halozyme Therapeutics (HALO) and argenx (ARGX) are expanding their existing global collaboration and license agreement that was signed in February 2019. Under the expanded deal, argenx gained the ability to exclusively access Halozyme's ENHANZE drug delivery technology for three addition...

Halozyme Announces Expansion Of Collaboration And License Agreement With argenx For ENHANZE® Technology PR Newswire SAN DIEGO, Oct. 6, 2020 SAN DIEGO , Oct. 6, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Halozyme ...

Genmab (GMAB) down 12% premarket in reaction to the announcement that it was locked in a legal battle with its partner Johnson & Johnson (JNJ) over royalty payments for its key cancer drug, source Reuters.Yesterday, GMAB commenced binding arbitration of two matters under license...